New CAR T targets for glioma currently tested in preclinical and clinical studies include: CD44 (41), CD70 (108), CD97 (109), CD133 (41), CD147 (110), C.TNC (DIPG) (111), CSPG4 (GBM) (112), GPC2 (DIPG, medulloblastoma) (113), EphA3 (114), MMP2 (40, 115), PD-L1 (GBM) (116), PTGFRN (117), ROBO1 (GBM) (71, 118, 119). Here, ROBO1 is linked to glioblastoma.